Vaccine against Ebola: Commission grants first-ever market authorisation

ebola news.jpg

Finnish Red Cross/Maria Santto Rinsing Ebola protective gear in Beni, Democratic Republic of the Congo.

This article is brought to you in association with the European Commission.


Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.V. for a vaccine against Ebola. This vaccine, called Ervebo, had been in development since the Ebola outbreak in West Africa in 2014. It is already used, as part of a specific protocol, to protect people at risk of infection, such as healthcare workers or people who have been exposed to infected persons.

This decision follows the recommendation from the European Medicines Agency (EMA), which has assessed the benefits and risks of the vaccine. It also follows the recent announcement of a clinical trial for a second Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) that is now under way in the Democratic Republic of Congo, with the support of the EU’s research and innovation programme Horizon 2020.

Vytenis Andriukaitis, Commissioner in charge of Health and Food Safety, said: “Finding a vaccine as soon as possible against this terrible virus has been a priority for the international community ever since Ebola hit West Africa five years ago. Today’s decision is therefore a major step forward in saving lives in Africa and beyond.”

Christos Stylianides, Commissioner for Humanitarian Aid and Crisis Management and EU Ebola Coordinator, said: “The EU is supporting international efforts to combat Ebola on all fronts, from vaccine development to delivering humanitarian aid on the ground. We will continue assisting the fight to tackle epidemic for as long as it takes.”

The clinical development of Ervebo was launched during the outbreak in West Africa five years ago. It was made possible through cooperation with public health stakeholders, which include national institutes of health, ministries of health in Africa (notably in Sierra Leone, Liberia, and Guinea), as well as the WHO, the Norwegian Institute of Public Health and Médecins Sans Frontières (MSF).

The development of the vaccine was supported by two projects from the Innovative Medicines Initiative (IMI) funded by the EU’s research and innovation programme Horizon 2020:

  • VSV-EBOVAC (March 2015-Feb. 2019), led by Academisch Ziekenhuis Leiden (NL) with €3.9 million EU contribution,
  • VSV-EBOPLUS (April 2016-March 2021), led by Merck Sharp & Dohme, with €8.5 million EU contribution.

Background

Ebola is a rare but severe illness caused by a virus of the same name. Death rates in patients who have contracted the disease have varied from 25% to 90% in past outbreaks. The largest outbreak to date occurred in West Africa in 2014-2016 with more than 11 000 deaths. The current outbreak in the Democratic Republic of Congo (DRC), caused by Ebola Zaire, has shown case fatality rates of approximately 67%. More than 3 000 people have been infected with the Ebola virus during the ongoing outbreak, which was declared a public health emergency of international concern by the World Health Organization (WHO) in July 2019. WHO extended this decision for another three months in October 2019.

The authorisation of a medicine under the centralised procedure is a two-stage process, involving the European Medicines Agency (EMA) and the European Commission.

EMA assesses the benefits and risks of medicines and makes recommendations to the Commission, which then takes a final legally binding decision on whether or not the medicine can be marketed in the EU.

This decision is issued normally within 67 days (legal deadline) of the scientific opinion of EMA (for Ervebo the date was 17 October). This phase includes, among other things, the translation of the product guidelines in all EU languages and a consultation with Member States (Comitology). In view of the public health interest, the Commission has accelerated this process and authorised the medicine in less than a month, in other words cutting the decision-making process in half.

The assessment report for Ervebo will be published on EMA’s website.

Moreover, the EU is part of the Innovative Medicines Initiative (IMI), a public-private partnership, which has supported the clinical development of the investigational preventive Ebola vaccines, as well as diagnostic tests through the IMI Ebola+ call.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

LGBTQI+ and medicine

This Indian school accepts plastic waste instead of fees

Health inequalities: private healthcare providers versus state healthcare providers

All sides in Yemen conflict could be guilty of war crimes, UN experts find

Fostering intergenerational solidarity and cooperation through age-friendly environments: the right answer to Europe’s demographic challenge

Why COVID-19 poses a particular threat in the world’s slums

At last Britain considers a super-soft Brexit

Mobile World Congress 2015 first to debate EU’s new stance on Net Neutrality and Roaming Charges

New SDG Advocates sign up for ‘peace, prosperity, people’ and planet, on the road to 2030

UN chief condemns attack targeting international forces in northern Mali

Fighting Terrorism Online: EU Internet Forum committed to an EU-wide Crisis Protocol

Cancer is a growing global threat and prevention is key, UN study shows

A very good morning in European markets

Bureaucracy in the member states again the obstacle for long due strong European Hedge Funds

Parliament requests further action to save EU tourism

Better protection against non-cash payment fraud

Amid Venezuela exodus, UN refugee envoy Angelina Jolie visits camps on Colombian border, appeals for humanity, more support

Finnish Council Presidency priorities debated in plenary

Wide-ranging reforms needed to ensure Italy’s economic recovery

New UN data tool shows ‘mismatch’ between government aid and places modern slavery exists

Corruption is rife in the COVID-19 era. Here’s how to fight back

What does the world really think about the UN Sustainable Development Goals?

The historic accomplishment of a seamless EU patent and intellectual property space

‘Stealing’ food from hungry Yemenis ‘must stop immediately’, says UN agency

What UK and EU risk if Brexit “wins” these elections

4 ways blockchain will transform the mining and metals industry

Quality Education on the table at the European Parliament

ECB bets billions on Eurozone’s economic recovery

Stateless Rohingya refugee children living in ‘untenable situation’, UNICEF chief

Dramatic drop in South Sudan political violence since peace agreement signing

State aid: Commission approves German aid scheme to support airports affected by the coronavirus outbreak

Iran protests: Live ammunition reportedly used, says UN human rights office

What changes in the EU as from today

UN peacekeepers warn of increasing global challenges

Deal on EU funds for common asylum, migration and integration policies up to 2027

Coronavirus: Using European supercomputing, EU-funded research project announces promising results for potential treatment*

How to build an entrepreneurial university

UNICEF delivers medical supplies to Gaza in wake of deadly protests

EU job-search aid worth €2 million for 500 former shipbuilding workers in Spain

How COVID-19 is taking gaming and esports to the next level

Powering through the pandemic

Permanent structured cooperation (PESCO) on the table of NATO Defense Ministers amid US concerns

A European young student speaks about the Youth Policies of the European Commission

7 of the world’s 10 most polluted cities are in India

South Africa’s cabinet is now 50% women for the first time ever

Ethiopian Prime Minister Abiy Ahmed wins Nobel Peace Prize

This chart shows the total number of COVID-19 cases and recoveries so far

Climate change and health: creating global awareness and using earth resources wisely

The Swiss will pay dearly for voting out fellow Europeans

Digital business is Europe’s best hope to get back to growth

Prospect of negotiated peace in Afghanistan ‘never been more real’ – UN mission chief

5 world-changing ideas: our top picks for World Creativity and Innovation Day

Why exporters need to mind the trade finance gap

Why collaboration will be key to creating the workforce of the future

Banking Union: ECOFIN and Parliament ready to compromise

Encouraging progress made in 2018, in ‘zero tolerance’ effort to end sexual exploitation and abuse across UN

The Fourth Industrial Revolution is changing how we grow, buy and choose what we eat

5 reasons why CEOs must care about safeguarding nature

Antitrust: Commission publishes report on the impact of the Interchange Fees Regulation

The Oslo model: how to prepare your city for the electric-vehicle surge

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s